{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:56:53Z","timestamp":1791341813305,"version":"4.3.1"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"21","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recombinant erythropoietin (EPO) analogs [erythropoiesis-stimulating agents (ESA)] are clinically used to treat anemia in patients with cancer receiving chemotherapy. After clinical trials reporting increased adverse events and\/or reduced survival in ESA-treated patients, concerns have been raised about the potential role of ESAs in promoting tumor progression, possibly through tumor cell stimulation. However, evidence is lacking on the ability of EPO to directly affect cancer stem\u2013like cells, which are thought to be responsible for tumor progression and relapse. We found that breast cancer stem\u2013like cells (BCSC) isolated from patient tumors express the EPO receptor and respond to EPO treatment with increased proliferation and self-renewal. Importantly, EPO stimulation increased BCSC resistance to chemotherapeutic agents and activated cellular pathways responsible for survival and drug resistance. Specifically, the Akt and ERK pathways were activated in BCSC at early time points following EPO treatment, whereas Bcl-xL levels increased at later times. In vivo, EPO administration counteracted the effects of chemotherapeutic agents on BCSC-derived orthotopic tumor xenografts and promoted metastatic progression both in the presence and in the absence of chemotherapy treatment. Altogether, these results indicate that EPO acts directly on BCSC by activating specific survival pathways, resulting in BCSC protection from chemotherapy and enhanced tumor progression. Cancer Res; 73(21); 6393\u2013400. \u00a92013 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-13-0248","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T03:54:54Z","timestamp":1378439694000},"page":"6393-6400","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stem\u2013like Cells to Protect Them from Chemotherapy"],"prefix":"10.1158","volume":"73","author":[{"given":"Matilde","family":"Todaro","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Turdo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bartucci","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Iovino","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Dattilo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Biffoni","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Stassi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Federici","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"De Maria","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Zeuner","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Surgical and Oncological Sciences, University of Palermo, Palermo; 2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanit\u00e0; 3Department of Surgical Sciences, University La Sapienza; and 4National Cancer Institute Regina Elena, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,10,31]]},"reference":[{"key":"2022061703522711800_bib1","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2004.12.027","article-title":"Weekly epoetin \u03b1 maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy","volume":"23","author":"Chang","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061703522711800_bib2","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/djp387","article-title":"Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer","volume":"101","author":"Hershman","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2022061703522711800_bib3","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"},{"key":"2022061703522711800_bib4","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","article-title":"Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials","volume":"373","author":"Bohlius","year":"2009","journal-title":"Lancet"},{"key":"2022061703522711800_bib5","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1200\/JCO.2008.19.1130","article-title":"Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia","volume":"27","author":"Ludwig","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061703522711800_bib6","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1503\/cmaj.090470","article-title":"Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis","volume":"180","author":"Tonelli","year":"2009","journal-title":"CMAJ"},{"key":"2022061703522711800_bib7","article-title":"Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy","volume-title":"U.S. Food and Drug Administration ODAC","year":"2007"},{"key":"2022061703522711800_bib8","article-title":"Risk evaluation and mitigation strategy BL 103234 EPOGEN\/PROCRIT (EPOETIN ALFA)","volume-title":"Administration FaD","year":"2010"},{"key":"2022061703522711800_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ccr.2010.10.025","article-title":"Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation","volume":"18","author":"Liang","year":"2010","journal-title":"Cancer Cell"},{"key":"2022061703522711800_bib10","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1158\/1078-0432.CCR-10-3298","article-title":"Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models","volume":"17","author":"Hedley","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061703522711800_bib11","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703522711800_bib12","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(11)70191-7","article-title":"Breast-cancer stem cells-beyond semantics","volume":"13","author":"Badve","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022061703522711800_bib13","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1172\/JCI59735","article-title":"Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis","volume":"122","author":"Battula","year":"2012","journal-title":"J Clin Invest"},{"key":"2022061703522711800_bib14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jnci\/djn123","article-title":"Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy","volume":"100","author":"Li","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2022061703522711800_bib15","doi-asserted-by":"crossref","first-page":"e15630","DOI":"10.1371\/journal.pone.0015630","article-title":"Markers of tumor-initiating cells predict chemoresistance in breast cancer","volume":"5","author":"Gong","year":"2010","journal-title":"PLoS ONE"},{"key":"2022061703522711800_bib16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Ginestier","year":"2007","journal-title":"Cell Stem Cell"},{"key":"2022061703522711800_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.stem.2007.08.001","article-title":"Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4","volume":"1","author":"Todaro","year":"2007","journal-title":"Cell Stem Cell"},{"key":"2022061703522711800_bib18","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1158\/0008-5472.CAN-05-0626","article-title":"Isolation and in vitro propagation of tumorigenic breast cancer cells with stem\/progenitor cell properties","volume":"65","author":"Ponti","year":"2005","journal-title":"Cancer Res"},{"key":"2022061703522711800_bib19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jcp.2011.090456","article-title":"Breast cancer stem cell markers CD44, CD24, and ALDH1: expression distribution within intrinsic molecular subtype","volume":"64","author":"Ricardo","year":"2011","journal-title":"J Clin Pathol"},{"key":"2022061703522711800_bib20","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood.V82.12.3760.3760","article-title":"Transcriptional and posttranscriptional regulation of the expression of the erythropoietin receptor gene in human erythropoietin-responsive cell lines","volume":"82","author":"Migliaccio","year":"1993","journal-title":"Blood"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/21\/6393\/2690090\/6393.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/21\/6393\/2690090\/6393.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:19:48Z","timestamp":1655471988000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/73\/21\/6393\/584783\/Erythropoietin-Activates-Cell-Survival-Pathways-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":20,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2013,10,31]]},"published-print":{"date-parts":[[2013,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-13-0248","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]}}}